AbbVie
ABBV
4,080 hedge funds and large institutions have $285B invested in AbbVie in 2026 Q1 according to their latest regulatory filings, with 189 funds opening new positions, 1,722 increasing their positions, 1,706 reducing their positions, and 180 closing their positions.
5% more first-time investments, than exits
New positions opened: 189 | Existing positions closed: 180
1% more repeat investments, than reductions
Existing positions increased: 1,722 | Existing positions reduced: 1,706
1.17% less ownership
Funds ownership: 74.74% → 73.57% (-1.2%)
2% less funds holding
Funds holding: 4,147 → 4,080 (-67)
5% less capital invested
Capital invested by funds: $302B → $285B (-$16.1B)
11% less call options, than puts
Call options by funds: $2.21B | Put options by funds: $2.5B
12% less funds holding in top 10
Funds holding in top 10: 199 → 175 (-24)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$1.88B |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$1.3B |
| 3 |
JP Morgan Chase
New York
|
+$965M |
| 4 |
DAM
Diamant Asset Management
Ridgefield,
Connecticut
|
+$811M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$782M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$2.71B |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.78B |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$1.74B |
| 4 |
Corient Private Wealth
Miami,
Florida
|
-$596M |
| 5 |
Morgan Stanley
New York
|
-$449M |
ABBV Hedge Fund Activity: Q1 2026 in Review
4,080 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2026, worth a combined $285B — down 5.4% from $302B a quarter earlier.
Buyers outnumbered sellers: 189 funds opened new ABBV positions and 180 closed out — a net gain of 9 holders — while 1,722 added to existing stakes and 1,706 trimmed.
The largest buyer was Fisher Asset Management, adding an estimated $1.88B. The largest seller was Charles Schwab, cutting an estimated $2.71B.
- 4,080 institutional investors held AbbVie (ABBV) as of Q1 2026, down from 4,147 in Q4 2025.
- Funds reported $285B of AbbVie stock for Q1 2026, down 5.4% quarter-over-quarter.
- 189 funds opened new AbbVie positions in Q1 2026 and 180 closed out, a net change of +9 holders.
- The largest AbbVie buyer in Q1 2026 was Fisher Asset Management, an estimated $1.88B added.
- The largest AbbVie seller in Q1 2026 was Charles Schwab, an estimated $2.71B sold.
Based on aggregated 13F filings for Q1 2026.